13 research outputs found
<i>ELF5</i> expression in normal breast and breast cancer.
<p><i>ELF5</i> expression in the UNC337 breast cancer cohort according to subtype. Top panel shows combined results with statistical analysis (thick black line, median;, box, interquartile range 25%–75% of points; whiskers, 1.5× interquartile range; crosses, individual tumors). Bottom panel <i>ELF5</i> expression in all individual tumor and normal samples. Basal and normal had significantly higher expression of ELF5.</p
ELF5 specifies breast cancer subtype.
<p>(A) Sub network of breast cancer subtype gene sets derived from forced ELF5 expression in MCF7 luminal breast cancer cells (inner node color) and knockdown of ELF5 expression in HCC1937 basal breast cancer cells. Node size is proportional to gene set size; thicker green lines indicate greater gene set overlap. Nodes are positioned according to similarity in gene sets. Labels in bold type indicate the functional significance of the four clusters generated, label is plain type is the gene set name. The full network is shown in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001461#pbio.1001461.s016" target="_blank">Figure S16</a>. (B–D) expression signature analysis of the ELF5-induced changes in molecular subtype produced by ELF5 knockdown in HCC1937 cells (B), or forced ELF5 expression in MCF7 cells (C), or T47D cells (D). Bars show the indicated comparisons that produce the associated <i>p</i>-values. BS, borderline significance; NS, not significant.</p
ELF5 suppresses the estrogen-sensitive phenotype.
<p>(A) Western blot showing reduced expression of key genes involved in the response to estrogens following induction of ELF5 expression. (B) Reduced transcriptional activity of reporters of <i>ER</i> and <i>FOXA1</i> (<i>UGT2B17</i> promoter) transcriptional activity following induction of ELF5 in MCF7 cells. Black bars, -DOX, grey bars +DOX 72 h for <i>ERE</i> and 24 h and 48 h for <i>FOXA1</i>. (C) Cell accumulation in MCF7-V5 cell cultures with (+E) or without (−E) 10 nM estrogen treatment, or following expression of ER (+ER) and 10 nM E in the context of induced ELF5. Black bars, -DOX; grey bars +DOX, 72 h and 144 h, respectively. (D) interaction of ELF5-regulated gene sets with estrogen-regulated gene sets. <i>p</i>-Values and odds ratios derived from hypergeometric tests. Number of genes in brackets. (E) Enrichment of gene sets in ELF5 ChIP targets either down (Dn) or Up in response to forced ELF5-V5 expression in T47D cells with DOX. P-Values for hypergeometric tests from GSEA (upper case) or Oncomine (lower case).</p
Visualization of the transcriptional functions of ELF5 in breast cancer.
<p>Affymetrix transcript profiling following induction of ELF5 in T47D and MCF7 luminal breast cancer cells, analysed by LIMMA and GSEA. <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001461#s2" target="_blank">Results</a> are visualized using the enrichment map plug-in for Cytoscape. Each circular node is a gene set with diameter proportional to the number of genes. The outer node color represents the magnitude and direction of enrichment (see scale) in T47D cells, inner node color enrichment in MCF7 cells. Thickness of the edges (green lines) is proportional to the similarity of gene sets between linked nodes. The most related clusters are placed nearest to each other. The functions of prominent clusters are shown. The network can be examined in detail using the scalable PDF in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001461#pbio.1001461.s004" target="_blank">Figure S4</a>.</p
Elf5 modulates the adhesion of breast cancer cells.
<p>(A) Quantification of detached cells in cultures treated with DOX (+D) compared to no induction (−D). (B) Ability of DOX-treated cells to replate 4 h after trypsin destruction of attachment proteins, compared to untreated cells. Data are expressed as a percentage of replated untreated cells. (C) Proportion of apoptotic cells in DOX treated (grey bars) compared to untreated (black bars) T47D-ELF5-V5 cells, measured by flow cytometry using the M30 antibody. (D) Expression and activation of key cell adhesion proteins following DOX induction of ELF5-V5 expression.</p
Chromatin immunoprecipitation and sequencing to identify genomic ELF5 binding sites.
<p>(A) Conservative analysis of the ChIP-Seq identified 1,763 peaks of ELF5 interaction with the genome at 48 h of DOX treatment, with a smaller number seen at 24 h. Relationship between enrichment and distance from binding peak is shown. (B) relationship between change in gene expression with 48 h of DOX treatment and distance of a peak of ELF5 DNA binding from the TSS. Blue area defines the region of random chance computed by multiple random assignments of the ChIP data to gene expression. Red line shows the actual relationship between a peak's distance from the nearest gene's TSS and its change in expression in response to ELF5-V5 induction. (C) ELF5 binding within the indicated genomic regions. (D) The number of genomic transcription factor binding motifs (TRANSFAC) found in the ChIP fragments relative to their enrichment. (E) example of an enriched peak of ELF5-V5 binding to DNA (<i>FOXA1</i> gene). (F) ChIP-qPCR validation of ELF5 binding sites to transcription factor gene promoters. I, IgG control antibody IP, E, ELF5 antibody IP, for the indicated PCR targets at 24 and 48 h; * significant (<i>p</i><0.05) enrichment against input; # significant enrichment against RND3 control gene; Δ significant 24 h versus 48 h. (G) GSEA of curated functional sets among ELF5 ChIP targets.</p
Elevated ELF5 allows escape from antiestrogen-induced proliferative arrest.
<p>(A) Affymetrix profiling of the expression (red high, green low) of key estrogen response genes in two models of antiestrogen resistance. The lines were derived from MCF7 cells from the Cardiff laboratory (MCF7C) to be resistant to TAMR or FASR. Additional two heat maps show the change in the expression of the ELF5 transcriptional signature in TAMR and FASR cells compared to parental. (B) PCR validation of the change in <i>ELF5</i> expression in TAMR and FASR cells. (C) Drug-response signatures from Oncomine enriched among genes implicated in antiestrogen resistance that are ELF5 ChIP targets. (D) Eduction in <i>ELF5</i> expression by estrogen treatment in MCF7C and TAMR cells. (E) Effects of ELF5 knockdown in TAMR cells on the expansion in cell number. Insets, demonstration of ELF5 knockdown by qPCR and IHC compared to both risc-free and scrambled siRNA controls. (F) BrdU labeling shows ELF5 knockdown inhibits cell proliferation in TAMR cells to a much greater extent than seen in the parental cells. (G) Model of ELF5 action in normal development and breast cancer, see the <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1001461#s3" target="_blank">Discussion</a> for details.</p
ELF5 produces hemorrhagic mammary tumors and increased tumor vasculature.
<p><b>Panel A</b>, appearance of PyMT-driven tumors in WT mice or those experiencing long-term (8 wk) forced expression of Elf5. <b>Panels B–D</b>, increased presence of erythrocytes (H&E), leukocytes (black arrows), and endothelial cells (white arrows), respectively (immunohistochemistry [IHC]), driven by ELF5, (scale bars 100μm). Flow cytometric (FC) quantification of these effects is shown in the right-hand side (RHS) panels. <b>Panel E</b>, measurement by immunofluorescence (IF) of CD31+ endothelium area (blue) in relation to the total cell area stained by DAPI (yellow). ImageJ quantification of random fields is shown in the RHS panel.</p
Elf5 immunohistochemistry as a predictor of luminal breast cancer survival.
<p>ELF5 was measured by immunohistochemistry in the cytoplasm and nucleus of tumors in a subset of ER+ samples from the Nottingham breast cancer series. <b>Panel A</b>, overall survival (OS) and <b>Panel B</b> distant metastasis free survival (DMFS). Hazards ratio (HR) and Log Rank <i>p</i>-value (p) are given for 5, 10, and 15 y of follow-up. Tumors are split into high ELF5 expression (green) and low Elf5 expression (blue) by XTile and <i>p</i>-values are black where >0.1, red where ≤0.05, and pink where 0.05–0.1.</p
Effects of forced Elf5 expression on tumor growth and cell autonomous pro-tumorigenic traits.
<p><b>Panel A</b>, PyMT mammary tumors showing heterogeneous expression of ELF5 visualized by EGFP expression. <b>Panel B</b>, percent primary tumor burden for each experimental group showing equivalence. <b>Panel C</b>, survival analysis of time to ethical endpoint (10% tumor burden), time to tumor detection, and time from detection to the ethical endpoint, in animals of the indicated genotypes carrying tumors that developed in situ. <b>Panel D</b>, survival analysis, as above, in animals carrying tumors that developed from an intraductal transplant of EGFP+ tumor cells derived from animals treated long term with DOX. Log-rank <i>p</i>-values are shown for +/- DOX comparison. N.S.; not significant. <b>Panel E</b>, representative image of cell proliferation measured by BrdU incorporation (red cells) in EGFP high (bright green) compared to EGFP low/no areas (dark green) of primary tumors, quantified by counting cells in random fields (bar chart). <b>Panels F and G</b>, Boyden chamber assays of motility and invasion through matrigel of EGFP high cells (PyMT ELF5) compared to wild-type PyMT cells separated by flow sorting. <b>Panel H</b>, lung colonies per field that developed from EGFP high or wild-type cells injected through the tail vein. <b>Panel I</b>, changes in gene expression of a set of genes involved in epithelial and mesenchymal characteristics. Significant increase in expression in red (UP), decrease in blue (DN), and nonsignificant changes in grey. Labels are EGFP- (G-), EGFP+ (G+) and WT (W). Raw data for panels E, F, G, and H can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.1002330#pbio.1002330.s001" target="_blank">S1 Data</a>.</p